As HMGB1-ferroptosis axis continues to expand mechanistically, further investigations are required to resolve the determinants and identify biomarkers of its pro- and anti-ferroptotic functions, as well as determine specific HMGB1 modulation to overcome therapy resistance in refractory cancers. The gene discussed is HMGB1; the disease is cancer.